Intrinsiqq
Sam Chun Dang Pharm Co., Ltd. logo

Sam Chun Dang Pharm Co., Ltd. Financials

000250.XKRX

Compare

All currency values in ₩ millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue₩259,900₩231,805₩210,924₩192,669₩177,335₩167,275
Cost of Revenue₩136,679₩122,429₩111,261₩95,702₩87,341₩84,197
Gross Profit₩123,221₩109,376₩99,662₩96,966₩89,995₩83,078
Total Operating Expenses₩105,474₩100,909₩97,020₩87,406₩77,770₩98,371
Operating Income₩17,747₩8,467₩2,642₩9,560₩12,225-₩15,293
Non-Operating
Net Interest Expense-₩825-₩980-₩383-₩2,577-₩2,793-₩1,897
Income Tax Expense₩4,198₩488₩16,116-₩361₩88-₩9,188
Net Income
Net Income₩25,475₩12,030-₩5,078-₩4,188₩8,832-₩10,361
Per Share Data
Revenue Per Share₩11,101.60₩9,956.24₩9,164.36₩8,591.73₩8,050.31₩7,578.07
EPS (Basic)₩864.02₩226.00-₩474.00-₩463.00₩265.00-₩750.00
EPS (Diluted)₩864.02₩226.00-₩474.00-₩463.00₩265.00-₩750.00
Shares Outstanding23.4M23.3M23.0M22.4M22.0M22.1M
Dividends Per Share₩50.00₩50.00₩200.00₩0.00₩0.00₩0.00

Sam Chun Dang Pharm Co. (000250.XKRX) financials: revenue, profit and margins

Sam Chun Dang Pharm Co. (000250.XKRX) generated about KRW 259.9 billion in revenue and KRW 25.5 billion in net income (a 9.8% net margin) over the trailing twelve months, growing at roughly 8.5% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Sam Chun Dang Pharm Co.'s (000250.XKRX) revenue?+

Sam Chun Dang Pharm Co. generated about KRW 259.9 billion in revenue over the trailing twelve months. Revenue has grown at roughly 8.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Sam Chun Dang Pharm Co. profitable?+

Yes, Sam Chun Dang Pharm Co. reported about KRW 25.5 billion in net income over the trailing twelve months, a net profit margin of roughly 9.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Sam Chun Dang Pharm Co.'s profit margins?+

Sam Chun Dang Pharm Co. runs a gross margin of about 47.4%, an operating margin of about 6.8%, a net margin of about 9.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Sam Chun Dang Pharm Co. growing?+

Sam Chun Dang Pharm Co.'s revenue has compounded at roughly 8.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside 000250.XKRX's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Held by ETFs

000250.XKRX is in 12 US ETFs. The largest of them, with 000250.XKRX's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing 000250.XKRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.